Jenny Beygo

Safety and immunogenicity of an MF59®-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly

Timo Vesikari, Aino Forstén, Karl–Heinz Herbinger et al. · Vaccine · 2011 · 55 citations

Vaccinology, Vaccine Safety, Cross-protection +8

Assessment of Antigen-Specific and Cross-Reactive Antibody Responses to an MF59-Adjuvanted A/H5N1 Prepandemic Influenza Vaccine in Adult and Elderly Subjects

Iván Bihari, Gyula Pánczél, József Kovács et al. · Clinical and Vaccine Immunology · 2012 · 32 citations · Full text

Dose-range Study of MF59-adjuvanted Versus Nonadjuvanted Monovalent A/H1N1 Pandemic Influenza Vaccine in Six- to Less Than Thirty-Six-month-old Children

Stan L. Block, Guillermo M. Ruiz‐Palacios, M. Lourdes Guerrero et al. · The Pediatric Infectious Disease Journal · 2012 · 25 citations

A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects.

Hanna Czajka, Serhat Ünal, Sercan Ulusoy et al. · PubMed · 2012 · 21 citations